The Six Domains of Dog Testing
Dog studies are not a single thing. They span six major domains, each with distinct protocols, durations, and levels of invasiveness. What they share is a common subject: a purpose-bred beagle, typically 4–6 months old at study start, housed in a steel-and-concrete kennel run for weeks to years. The dominant global driver is regulatory nonclinical safety assessment — repeat-dose toxicology, safety pharmacology, and PK/ADME — because these are standardized across sponsors and CROs, required for progression to human trials, and repeatedly purchased.
Repeat-Dose Toxicology
REG-SYSDaily oral dosing for weeks to months, followed by necropsy. The single largest driver of dog use in labs worldwide. OECD TG 409 specifies beagles as the commonly used non-rodent, minimum 32 dogs per study.
Safety Pharmacology
REG-CV/RESP/CNSICH S7A core battery: cardiovascular telemetry (BP, HR, ECG), respiratory function, and CNS assessment. Often requires surgical implantation of telemetry devices under general anesthesia, with 14+ day recovery before dosing begins.
ADME / Pharmacokinetics
REG-PKAbsorption, distribution, metabolism, and excretion characterization. Dense serial blood sampling (e.g., 11 draws in 24 hours), metabolism cage housing for excreta collection, and often catheter/port implantation for automated sampling.
Medical Device Testing
DEV-IMPLSurgical implantation of cardiovascular, orthopedic, and other devices to evaluate safety, performance, and biocompatibility in living tissue. Ends with explant surgery and histopathology of the implant site.
Newer and Specialized Areas
DIS/INF/WD/NUTDisease models and translational research (oncology, spinal cord injury), pain research, vaccine challenge studies, gene therapy, working-dog performance science, and pet food palatability/feeding trials.
Study Design and Oversight
Cross-cuttingHow studies are designed, reviewed, and reported. GLP requirements (21 CFR Part 58), IACUC oversight, severity classification systems (EU vs USDA), and the cumulative burden framework that determines what a dog actually experiences.
Procedure Deep Dives
Detailed pages on individual procedures, surgical interventions, and historical practices.
Inside a Gavage Dosing Session
Oral gavage is the most common dosing route in repeat-dose toxicology. A flexible tube or cannula is passed through the mouth into the stomach, delivering the test compound directly. In OECD TG 409 studies, this happens daily for 90 consecutive days. Known complications include reflux, aspiration pneumonia, and tissue irritation — a pathology review of control beagles found aspiration pneumonia more common in gavage-study dogs than in capsule-dosed controls.
Oral Gavage: How a Beagle Is Force-Fed
The most common dosing method in toxicology studies — performed daily for weeks to months
The Procedure (Daily)
Dog placed in a sling or held by a technician. Head tilted upward to straighten the esophagus.
A flexible tube (gavage needle) is inserted through the mouth, past the pharynx, down the esophagus, into the stomach.
Test substance delivered via syringe directly to the stomach. Volume based on body weight (typically mL/kg).
Tube removed. Dog monitored briefly for aspiration or distress. Returned to cage.
Same procedure daily — for 28 days, 90 days, or up to 12 months depending on study design.
Risk: Aspiration pneumonia if the tube enters the trachea instead of the esophagus. This is a documented cause of death in gavage studies.
Oral gavage is performed on 27,909+ dogs per year (USDA Column C+D). The procedure is classified as 'no pain' or 'pain with relief' — but the dog is restrained and a tube is forced down its throat daily.
Source: OECD TG 409; GLP toxicology study protocols; veterinary procedure references
Why ~95% Are Killed at Study End
The overwhelming majority of dogs in regulatory studies are euthanized at study conclusion. This is not incidental — it is built into the study design. Regulatory toxicology requires necropsy and histopathological examination of a standardized tissue list to identify target-organ toxicity, determine dose-response relationships, and assess reversibility of findings. Without terminal tissue collection, the study cannot fulfill its regulatory purpose.
Repeat-dose toxicology (28–90 days): All main-study animals are euthanized and necropsied. Recovery satellite groups — if included — are held an additional 2–4 weeks to assess reversibility, then also euthanized for histopathology.
Chronic studies (6–12 months): Terminal necropsy at study end. Interim sacrifices may occur at planned timepoints if the protocol requires progressive tissue evaluation.
Device testing: Explant histology requires euthanasia to evaluate local tissue response and device integrity at the implant site.
Exceptions: Safety pharmacology telemetry dogs are sometimes reused across multiple cross-over studies — EU data shows 5,659 dog reuses in 2022. PK/ADME studies can be non-terminal. Pet-patient translational studies return dogs to owners. But these are the minority.
Global Taxonomy: Who Tests What
Dog testing is shaped by international harmonized frameworks — OECD test guidelines and ICH safety guidance form the regulatory “spine” across the US, EU, Japan, and China. But regional differences in adoption, conditional requirements, and reporting create meaningful variation in how many dogs are used, for what, and whether the numbers are even publicly disclosed.
United States
42,880 dogs (FY2024)Regulatory toxicology, safety pharmacology, device testing, military/detection research
USDA AWA reporting. 27,909 used with no pain; 12,176 pain minimized; 410 pain not minimized.
EU + Norway
8,709 dogs (2022)Regulatory toxicology, ADME/PK, translational veterinary research
Down 41% from 14,802 in 2018. 5,659 reuses reported. One-year dog study no longer required for pesticides.
Japan
Not centrally published dogsICH-aligned regulatory packages, conditional chronic studies
Food Safety Commission states one-year dog study is not a universal prerequisite for pesticide evaluation.
China
Not centrally published dogsICH-aligned since 2017, growing CRO capacity
NMPA adopted multiple ICH safety guidelines. Aligning with ICH weakens dog-specific mandates in favor of justified non-rodent selection.
Cumulative Burden: Why “Routine” Adds Up
No single procedure tells you what a dog experiences. The actual burden comes from the combination and repetition of procedure modules — dosing, restraint, blood sampling, housing constraints, and monitoring — stacked across days, weeks, and months. UK and EU severity guidance explicitly states that overall classification should increase when harms are cumulative: repeated mild events without recovery, or prolonged mild suffering, can elevate a study from “mild” to “moderate” or higher.